Please login first
Valentina Onnis   Professor  Senior Scientist or Principal Investigator 
Timeline See timeline
Valentina Onnis published an article in August 2018.
Research Keywords & Expertise See all
0 A
0 Synthesis
0 extracted
0 leading journals
0 Full Text
0 anticancer activity
Top co-authors See all
Claudiu T. Supuran

765 shared publications

Department of Neuroscience, Psychology, Drug Research and Child’s Health, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy

Jan Balzarini

70 shared publications

KU Leuven—University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven B-3000, Belgium

Valentina Onnis

49 shared publications

Dipartimento di Scienze della Vita e dell’Ambiente, Sezione di Scienze Farmaceutiche, Farmacologiche e Nutraceutiche, Università degli Studi di Cagliari, Via Ospedale 72, Cagliari I-09124, Italy

Cenzo Congiu

39 shared publications

University of Cagliari

Sandra Liekens

33 shared publications

KU Leuven—University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven B-3000, Belgium

48
Publications
30
Reads
8
Downloads
260
Citations
Publication Record
Distribution of Articles published per year 
(1992 - 2018)
Total number of journals
published in
 
21
 
Publications See all
Article 0 Reads 0 Citations Benzofuran hydrazones as potential scaffold in the development of multifunctional drugs: Synthesis and evaluation of ant... Anna Baldisserotto, Monica Demurtas, Ilaria Lampronti, David... Published: 01 August 2018
European Journal of Medicinal Chemistry, doi: 10.1016/j.ejmech.2018.07.001
DOI See at publisher website
Article 0 Reads 3 Citations Discovery of thiazolin-4-one-based aromatic sulfamates as a new class of carbonic anhydrase isoforms I, II, IV, and IX i... Alessio Nocentini, Davide Moi, Gianfranco Balboni, Valentina... Published: 01 April 2018
Bioorganic Chemistry, doi: 10.1016/j.bioorg.2018.01.023
DOI See at publisher website
Article 0 Reads 0 Citations Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoform... Alessio Nocentini, Davide Moi, Gianfranco Balboni, Severo Sa... Published: 01 April 2018
Bioorganic Chemistry, doi: 10.1016/j.bioorg.2018.02.021
DOI See at publisher website
Article 0 Reads 0 Citations 3,4-Dihydroquinazoline derivatives inhibit the activities of cholinesterase enzymes Byeongyeon Park, Ji Hye Nam, Jin Han Kim, Hyoung Ja Kim, Val... Published: 01 March 2017
Bioorganic & Medicinal Chemistry Letters, doi: 10.1016/j.bmcl.2017.01.068
DOI See at publisher website PubMed View at PubMed
Article 0 Reads 3 Citations Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro Elisa Landucci, Roberta Lattanzi, Elisabetta Gerace, Tania S... Published: 01 September 2016
Neuropharmacology, doi: 10.1016/j.neuropharm.2016.04.043
DOI See at publisher website PubMed View at PubMed
Article 3 Reads 4 Citations Design, Synthesis and Evaluation of Antiproliferative Activity of New Benzimidazolehydrazones Valentina Onnis, Monica Demurtas, Alessandro Deplano, Gianfr... Published: 30 April 2016
Molecules, doi: 10.3390/molecules21050579
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
The synthesis and antiproliferative activity of new benzimidazole derivatives bearing an hydrazone mojety at the 2-position is described. The new N′-(4-arylidene)-1H-benzo[d]imidazole-2-carbohydrazides were evaluated for their cytostatic activity toward the murine leukemia (L1210), human T-cell leukemia (CEM), human cervix carcinoma (HeLa) and human pancreas carcinoma cells (Mia Paca-2). A preliminary structure-activity relationship could be defined. Some of the compounds possess encouraging and consistent antiproliferative activity, having IC50 values in the low micromolar range.
Conference papers
CONFERENCE-ARTICLE 24 Reads 0 Citations Discovery of novel endocannabinoid level modulators by modification of old analgesic drugs Alessandro Deplano, Monica Demurtas, Valentina Onnis Published: 31 October 2018
doi: 10.3390/ecmc-4-05590
DOI See at publisher website ABS Show/hide abstract

Fatty acid amide hydrolase (FAAH) is a serine hydrolase that catalyzes the deactivating hydrolysis of the fatty acid ethanolamide family of signaling lipids, which includes anandamide (AEA), an endogenous ligand for cannabinoid receptors. Endogenous FAAH substrates such as AEA serve key regulatory functions in the body and have been implicated in a variety of pathological conditions including pain, inflammation, sleep disorders, anxiety, depression, and vascular hypertension, and there has been an increasing interest in the development of inhibitors of this enzyme.
Different structural classes of FAAH inhibitors have been reported including alpha-ketoheterocycles, (thio)hydantoins, piperidine/piperazine ureas, and carbamate derivatives. When tested, these compounds have been shown to be efficacious in models of inflammatory, visceral, and in some cases
neuropathic pain without producing the central effects seen with directly acting cannabinoid receptor agonists. An intriguing aspect of FAAH inhibition is that some currently marketed nonsteroidal anti-inflammatory drugs (NSAIDs) have also been shown to be weak inhibitors of FAAH, but can be used as a template for the design of more potent compounds. However, structure–activity relationships of analogues of clinically used NSAIDs with respect to FAAH inhibition have been examined scarcely in the literature. These findings led us to design and synthesis of new series of FAAH inhibitors derivable from conjugation of heterocyclic structures with NSAIDs as profens, fenamates, and new their correlate molecules. In this keynote we report on the synthetic pathways to transform old analgesic drugs into FAAH inhibitors and SAR studies on the new inhibitor series.

Top